The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. The ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive ...

The nasal spray, Spravato, has had its approval expanded to be used as a standalone treatment for depression.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved the nasal spray Spravato as a treatment for severe depression.

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVYTM (nipocalimab-aahu) for the treatment of ...

The FDA on Tuesday held a panel discussion on the alleged risks of talcum powder. Talc, an anti-caking agent that is mined from rock, is prevalent in food and pharmaceutical products.

Galdieria extract blue, butterfly pea flower extract and calcium phosphate are three food colors from natural sources the FDA has approved for use in food.

The FDA’s approval was based on a study of 11,400 people ages 12 and older that compared the new low-dose vaccine with Moderna’s existing vaccine.

The FDA approves Imaavy, a groundbreaking treatment for generalized myasthenia gravis (gMG), offering symptom relief and reduced autoantibody levels in adults and children over 12.